Page last updated: 2024-11-12

dsp 4 hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID11957497
CHEMBL ID1255650
SCHEMBL ID2268042
MeSH IDM0311735

Synonyms (34)

Synonym
EU-0100299 ,
n-(2-chloroethyl)-n-ethyl-2-bromobenzylamine hydrochloride, >=98%, solid
MLS000859958
smr000326817
n-(2-chloroethyl)-n-ethyl-2-bromobenzylamine hydrochloride
dsp-4
NCGC00093749-01
dsp-4 hydrochloride
C 8417
CHEMBL1255650
40616-75-9
LP00299
SCHEMBL2268042
AKOS024457354
sr-01000075248
SR-01000075248-1
n-(2-bromobenzyl)-2-chloro-n-ethylethanamine hydrochloride
FT-0726819
n-(2-chloroethyl)-n-ethyl-2-bromobenzylaminehydrochloride
DTXSID601017240
n-(2-bromobenzyl)-2-chloro-n-ethylethanamine hydrochloride (1:1)
neurotoxin dsp 4 (hydrochloride)neurotoxin dsp 4 (hydrochloride)
dsp-4 (hydrochloride)
HY-103210
CS-0025301
neurotoxin dsp 4 (hydrochloride)
D81991
[(2-bromophenyl)methyl](2-chloroethyl)ethylamine hydrochloride
AS-57238
n-[(2-bromophenyl)methyl]-2-chloro-n-ethylethanamine;hydrochloride
n-(2-bromobenzyl)-2-chloro-n-ethylethanaminehydrochloride
A937278
EN300-7505278
n-(2-bromobenzyl)-2-chloro-n-ethylethan-1-amine hydrochloride
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency5.62340.003245.467312,589.2998AID2517
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
Chain A, Ferritin light chainEquus caballus (horse)Potency31.62285.623417.292931.6228AID2323
endonuclease IVEscherichia coliPotency39.81070.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency23.31610.100020.879379.4328AID588453
TDP1 proteinHomo sapiens (human)Potency22.72650.000811.382244.6684AID686978; AID686979
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00280.540617.639296.1227AID2364; AID2528
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency29.93490.168316.404067.0158AID720504
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency22.38720.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency5.00230.004611.374133.4983AID624296; AID624297
M-phase phosphoprotein 8Homo sapiens (human)Potency0.79430.177824.735279.4328AID488949
lamin isoform A-delta10Homo sapiens (human)Potency14.12540.891312.067628.1838AID1459
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency11.22021.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1124028Inhibition of [3H]dopamine reuptake at DAT in Sprague-Dawley rat brain striatal synaptosomes incubated for 5 mins prior to [3H]dopamine addition measured after 3 mins by scintillation counting analysis1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Inhibition of uptake of catecholamines by benzylamine derivatives.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1124029Selectivity ratio of I50 for [3H]dopamine reuptake at DAT in Sprague-Dawley rat brain striatal synaptosomes to I50 for [3H]norepinephrine reuptake at NET in Sprague-Dawley rat brain cortical synaptosomes1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Inhibition of uptake of catecholamines by benzylamine derivatives.
AID1124027Inhibition of [3H]norepinephrine reuptake at NET in Sprague-Dawley rat brain cortical synaptosomes incubated for 5 mins prior to [3H]norepinephrine addition measured after 3 mins by scintillation counting analysis1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Inhibition of uptake of catecholamines by benzylamine derivatives.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's2 (28.57)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.06 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]